All In Biotech

NDA 018907 · Hikma

Metronidazole

Metronidazole · Injection

Discontinued

Last checked: Nov 20, 2026Latest source record: Jan 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Mar 30, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

132 Phase 3, 52 recruiting

FAERS reports

48,098

41,903 serious, 5,412 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 30, 1984 Original approval
1 products under this application
  • METRONIDAZOLE · METRONIDAZOLE 500MG/100ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Metronidazole" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,656
  • nausea3,459
  • off label use3,383
  • diarrhoea2,713
  • vomiting2,330
  • pyrexia2,288
  • headache2,259
  • abdominal pain2,119
  • pain2,119
  • fatigue1,959
  • dizziness1,684
  • condition aggravated1,634

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004459
2005480
2006482
2007511
2008320
2009676
2010858
20111,164
20121,431
20131,112
20141,451
20152,167
20162,471
20172,508
20184,185
20194,490
20203,820
20213,868
20223,400
20233,458
20243,160
20253,437
20262,187

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Metronidazole (Metronidazole/Sodium Chloride)

2024 spending

$64K

Beneficiaries

1,192

2,603 claims

Per beneficiary

$54

$0.02 per unit

View as table
YearSpending
2020$83,174
2021$63,002
2022$60,654
2023$74,204
2024$64,373

Part D: Metronidazole* (Metronidazole)

2024 spending

$56.4M

Beneficiaries

1,629,321

2,260,622 claims

Per beneficiary

$35

$0.59 per unit

View as table
YearSpending
2020$75,483,136
2021$72,736,230
2022$69,995,249
2023$70,489,119
2024$56,406,313

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,032 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.